American Express Company vs Amgen Inc.: Strategic Comparison

This in-depth comparison examines American Express Company and Amgen Inc. across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching American Express Company on its own, evaluating Amgen Inc., or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between American Express Company and Amgen Inc. is widest.

On the headline numbers, American Express Company reports annual revenue of $72.2B against $36.8B for Amgen Inc., while their respective market capitalizations stand at $205.8B and $228.2B. Both American Express Company and Amgen Inc. are headquartered in United States, so they compete in a shared home market and regulatory environment.

American Express Company: American Express is a payments company that sells access to its own card members. It does not rent its network to thousands of issuing banks the way Visa and Mastercard do; it issues the cards, signs the merchants and keeps the discount fee. In FY2025 it carried $1,897.0 billion of network volumes, had 152.8 million cards in force worldwide including 86.6 million it issues itself, and reported $72.2 billion in total revenues net of interest expense. The premium lineup runs from the Green Card up through the Gold Card at $325 a year, the Platinum Card at $895 after its September 2025 refresh, and the invitation-only Centurion Card, whose fee the company does not publish.

Amgen Inc.: Amgen is one of the companies that created the biotechnology industry. Instead of synthesizing small-molecule drugs, it engineers living cells to make complex proteins, an approach it first commercialized with Epogen in 1989. Based in Thousand Oaks, California, it is best known for medicines in bone health, inflammation, cardiovascular disease and kidney disease, and since the 2023 Horizon acquisition in rare disease. Fiscal 2025 revenue was US$36.8 billion across a portfolio in which 14 products each sold more than US$1 billion, although several of the older brands are now losing both price and volume.

American Express Company and Amgen Inc. pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between American Express Company and Amgen Inc..

American Express Company business model: American Express runs a closed-loop payments business: it issues the card, owns the network, underwrites the credit and contracts with the merchant. Visa and Mastercard only move the transaction between an issuing bank and an acquiring bank, so they never see both sides of a purchase. Because Amex holds every side of the relationship, it keeps the whole merchant discount fee rather than sharing it, and in FY2025 discount revenue equalled 2.24 percent of the $1,669.8 billion its card members billed. The trade-off is price: merchants pay more to accept Amex than to accept an open-loop card, so the company has to justify the rate with card members who spend more. Average spending per proprietary basic card member was $25,453 in 2025. Amex funds that proposition with annual fees, which reached $10.0 billion in net card fees in FY2025 at an average of $117 per proprietary card, and spends the money back on Membership Rewards, the Centurion Lounge network, Resy and Tock dining access and service. Since converting to a bank holding company in 2008 it has also lent against card balances through American Express National Bank, producing $17.4 billion of net interest income in FY2025.

Amgen Inc. business model: Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price. Because biologic drugs are grown from living cells rather than chemically synthesized, they are much harder for competitors to copy, resulting in slightly longer and more defensible monopolies than traditional pills.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of American Express Company stack up against those of Amgen Inc..

American Express Company competitive advantage: American Express competes on the spending power of its card members rather than on price or ubiquity. Average spending per proprietary basic card member was $25,453 in 2025, which is the argument it makes to merchants who pay a higher discount rate, an average of 2.24 percent of billed business. Owning both sides of the transaction also gives it card member and merchant data that open-loop networks do not hold, which feeds underwriting and targeted offers. Credit outcomes reflect the customer mix: a 2.0 percent net write-off rate on consumer and small business loans and receivables in 2025, with 1.3 percent of balances 30 or more days past due.

Amgen Inc. competitive advantage: Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989. Producing a glycosylated protein or a monoclonal antibody to a consistent specification requires validated facilities, process know-how and a regulatory record that take years to build, which is also why the company can turn the same capability toward biosimilars of competitor products. Its balance sheet lets it buy late-stage assets rather than rely only on internal discovery: Onyx, Otezla, Five Prime, ChemoCentryx and Horizon together cost about US$57 billion between 2013 and 2023.

Future prospects matter as much as current results. The growth strategies below explain how American Express Company and Amgen Inc. each plan to expand from here.

American Express Company growth strategy: Amex's growth strategy is aggressively focused on capturing the next generation of wealthy spenders: Millennials and Gen Z. They have successfully revamped their well-known Platinum and Gold cards with perks tailored specifically for younger demographics (like Uber credits and dining rewards), resulting in rapid growth among younger cohorts. Additionally, they are heavily targeting small and medium-sized businesses (SMBs), aggressively expanding their corporate card and B2B payment processing services to capture large commercial spending volumes.

Amgen Inc. growth strategy: Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year. The company is pushing into obesity with MariTide, now in six Phase 3 MARITIME studies, and runs a biosimilars business that produced about US$3.0 billion of fiscal 2025 sales across Pavblu, Mvasi, Amjevita and Wezlana.

A closer look at the financial trajectory of American Express Company and Amgen Inc. rounds out the comparison.

American Express Company: American Express reported $72.2 billion in total revenues net of interest expense for FY2025, up 10 percent, and $10.8 billion of net income, or $15.38 per diluted share. The mix is less fee-only than its premium image suggests: discount revenue on merchant transactions was $37.4 billion, net interest income on card member loans was $17.4 billion, net card fees were $10.0 billion and service fees and other revenue were $7.5 billion. Growth in 2025 came disproportionately from the two smaller lines, with net card fees up 18 percent and net interest income up 12 percent against 6 percent growth in discount revenue. Return on average equity was 33.9 percent, the net write-off rate on consumer and small business loans and receivables was 2.0 percent, and the company declared $3.28 per share in dividends while average diluted shares fell from 713 million to 696 million.

Amgen Inc.: Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025.